Streetbeat News

Analyst Ratings

ANVS

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Annovis Bio (NYSE:ANVS) and maintained a $40 price target.

Portfolio Pulse from richadhand@benzinga.com

June 28, 2023 | 10:16 am

BYDDF

BYDDY

TSLA

Tesla's Q2 sales in China are expected to increase by 13% quarter-over-quarter to 155,000 units, despite its market share in the battery EV market likely shrinking from 16% to 13.7%, according to China Merchants Bank International Securities analyst Shi Ji. Other domestic players such as BYD have seen their market share increase. Tesla's direct sales model could make expansion into lower-tiered cities expensive. China is a key market for Tesla, with about half of its total production coming from the country.

Portfolio Pulse from Shanthi Rexaline

June 28, 2023 | 10:16 am

ACIU

HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on AC Immune (NASDAQ:ACIU) and maintained a $16 price target.

Portfolio Pulse from richadhand@benzinga.com

June 28, 2023 | 10:16 am

ZI

Needham has reiterated its 'Buy' rating on ZoomInfo Technologies (NASDAQ:ZI) and maintained its price target of $35.

Portfolio Pulse from richadhand@benzinga.com

June 28, 2023 | 10:15 am

RGLS

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Regulus Therapeutics (NASDAQ:RGLS) and maintained a $9 price target.

Portfolio Pulse from richadhand@benzinga.com

June 28, 2023 | 10:14 am

RZLT

HC Wainwright & Co. analyst Douglas Tsao has reiterated a 'Buy' rating on Rezolute (NASDAQ:RZLT) and maintained a $14 price target.

Portfolio Pulse from richadhand@benzinga.com

June 28, 2023 | 10:14 am

MDNA

HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a 'Buy' rating on Medicenna Therapeutics (NASDAQ:MDNA) and maintained a price target of $2.5.

Portfolio Pulse from richadhand@benzinga.com

June 28, 2023 | 10:12 am

BCTX

HC Wainwright & Co. analyst Emily Bodnar has reiterated a 'Buy' rating on BriaCell Therapeutics (NASDAQ:BCTX) and maintained a $25 price target.

Portfolio Pulse from richadhand@benzinga.com

June 28, 2023 | 10:12 am

CNTG

HC Wainwright & Co. analyst Yi Chen has reiterated a 'Buy' rating on Centogene (NASDAQ:CNTG) and maintained a price target of $1.5.

Portfolio Pulse from richadhand@benzinga.com

June 28, 2023 | 10:11 am

GMAB

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Genmab (NASDAQ:GMAB) and maintained a $51 price target.

Portfolio Pulse from richadhand@benzinga.com

June 28, 2023 | 10:10 am